This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
25 May 2012

IMI Launches Project on Antimicrobials

The Innovative Medicines Initiative launches a €223.7m programme aimed at tackling antibiotic resistance issue.

The Innovative Medicines Initiative (IMI) is launching a €223.7m programme aimed at tackling antibiotic resistance and speeding up the delivery of new antibiotics to patients.

 

Leading academics and five major pharmaceutical firms (GlaxoSmithKline, AstraZeneca, Janssen, Sanofi and Basilea Pharmaceutica) will collaborate in the project, which is part of the European Commission’s Action Plan against the rising threats from Antimicrobial Resistance, introduced last November.

 

The first set of projects has been launched on 24 May with a joint budget of €223.7m, consisting of €109m from the IMI and €114.7m provided by in-kind contributions from participating European Federation of Pharmaceutical Industries and Associations (EFPIA) members.

 <

Related News